Phaseline

Companies › Sichuan Clover Biopharmaceuticals

Sichuan Clover Biopharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Hematology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SCB-219M
TNF receptor II-Fc fusion protein with TPO mimetic peptide
TNFRSF1B, THPOPhase 1Chemotherapy-induced Thrombocytopenia (CIT)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05426369SCB-219MPhase 1Chemotherapy-induced Thrombocytopenia (CIT)HematologyJul 2025

Targets

TNFRSF1B (1) THPO (1)

Companies with the same targets

Geropharm MIBIO PTE. Chongqing Peg-Bio Biopharm

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.